Updated Results from KEYNOTE-564 Confirm Benefit of Adjuvant Pembrolizumab for Patients with Renal-Cell Carcinoma at High Risk for Recurrence

Press/Media

Period	Jul 20 2022

Media coverage

Title	Updated Results from KEYNOTE-564 Confirm Benefit of Adjuvant Pembrolizumab for Patients with Renal-Cell Carcinoma at High Risk for Recurrence
Media name/outlet	Oncology Pharmacist.com
Country/Territory	United States
Date	07/20/22
URL	https://theoncologypharmacist.com:443/top-issues/2022-issues/july-2022-vol-15-no-4/19175-updated-results-from-keynote-564-confirm-benefit-of-adjuvant-pembrolizumab-for-patients-with-renal-cell-carcinoma-at-high-risk-for-recurrence
Persons	Daniel Geynisman